A phase III clinical trial of PexaVec, a VV containing the immune-stimulatory cytokine GM-CSF, in hepatocellular carcinoma also failed due to an inability to outperform standard-of-care chemotherapy (http://ClinicalTrials.gov, NCT02562755). This evidence concerns the gene CSF2 and hepatocellular carcinoma.